What is the role of antiangiogenesis agents in the treatment of breast cancer?

Updated: May 21, 2019
  • Author: Erin V Newton, MD; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print


CALGB 40603 was a 2x2 randomized open-label neoadjuvant study evaluating the addition of bevacizumab and/or carboplatin to a weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide (ddAC).  The pCR rate was higher in the bevacizumab-treated subjects, although not at statistical significance.  Furthermore, the toxicity of the bevacizumab-containing arms, including hypertension, febrile neuropenia, and postoperative complications has led the authors to speculate that bevacizumab has no role in early stage breast cancer.  Bevacizumab is not currently used in neoadjuvant therapy for breast cancer.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!